Evgen Pharma Share Price (EVG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Evgen Pharma	LSE:EVG	London	Ordinary Share	GB00BSVYN304	ORD 0.25P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	13.00p	72,205	06:35:19
Bid Price		Offer Price	High Price	Low Price	Open Price
12.50p		13.50p	13.00p	13.00p	13.00p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-3.6	-4.2	-	12.13

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Evgen Pharma (EVG) Latest News (1)

Evgen Pharma News

Date	Time	Source	Headline
24/4/2018	07:00	UKREG	Evgen Pharma PLC Presentation at World Orphan Drug Congress USA
20/3/2018	13:56	ALNC	Evgen Pharma Begins Research Partnership With Imperial College London
20/3/2018	07:28	ALNCF	Alliance News Flash Headline
20/3/2018	07:00	UKREG	Evgen Pharma PLC Research Collaboration with Imperial College
05/3/2018	12:02	ALNC	Evgen Pharma Receives Positive Sulforaphane Results From Evaulation
05/3/2018	07:00	UKREG	Evgen Pharma PLC Update on Novel Sulforaphane Analogues
15/1/2018	13:05	ALNC	Evgen Says SFX-01 Could Improve Endocrine Therapy For Breast Cancer
15/1/2018	07:00	UKREG	Evgen Pharma PLC Poster Presentation of SFX-01 Mechanistic Data
10/1/2018	17:56	ALNC	Seneca Partners Almost Doubles Evgen Pharma Stake To 7.4% (ALLISS)
10/1/2018	16:31	UKREG	Evgen Pharma PLC Notification of Major Interest in Shares

More Evgen Pharma News

Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date	Time	Title	Posts
24/4/2018	09:32	Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer	133
26/6/2017	07:38	Evgen Pharma Plc Investor Presentation	-
13/6/2017	09:45	Evgen Pharma Interview	-
29/11/2016	08:27	Evgen Pharma (EVG) chief executive Stephen Franklin	39
24/8/2016	15:30	EVG	39

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
16:15:43	13.45	50,000	6,725.00	O
15:12:27	12.70	9,697	1,231.52	O
11:45:36	12.70	5,047	640.97	O
11:43:47	13.30	7,461	992.31	O

View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Date	Subject
24/4/2018 09:20	Evgen Pharma Daily Update: Evgen Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 13p. Evgen Pharma has a 4 week average price of 12.25p and a 12 week average price of 12.25p. The 1 year high share price is 29.38p while the 1 year low share price is currently 12p. There are currently 93,276,858 shares in issue and the average daily traded volume is 69,568 shares. The market capitalisation of Evgen Pharma is £12,125,991.54. Read Full Thread Reply
13/12/2017 10:16	rathean: Agreed #Tilly99, share price discounts huge upside. Great entry point, it'll rise quickly when it goes Read Full Thread Follow Reply
09/12/2017 13:51	dave444: I would not be surprised if it hit 12p but a £1/share price would not surprise me by February Read Full Thread Follow Reply
24/11/2017 00:37	timbo003: There doesn't seem to be any material event behind the recent rise, so presumably the reason is just another Pump and Dump. However, if the share price ends up higher than where it started , it will have served a useful purpose. I suspect the company will want to find a bit of cash from somewhere before they get the first readout from the two ongoing clinical studies and according to the last Hardman report they will be running on empty by March next year. If the cash is to come from an equity based fund raise (which seems likely), then the higher the price the better as far as I am concerned. Read Full Thread Follow Reply
23/11/2017 11:07	ny boy: The Company needs to issue a statement re the share price rise, I think it will come in the next few hours. Read Full Thread Follow Reply
26/9/2017 11:31	pdt: Another good piece of research on Sulforaphane and breast cancer; Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells hTTp://www.thno.org/v07p3461.htm A bit disappointing that the share price is drifting lower. That will not help the inevitable fund raise. Hopefully, there will be some positive news before they complete that. I have been buying on the way down but now I have probably as many as I want to hold at this stage. Read Full Thread Follow Reply
15/2/2017 08:14	timbo003: This week's (unexpected) performance has to be worth an animated gif! I'm not sure what the catalyst is for this recent rise, a patent grant (even in the US) doesn't normally have an effect of this magnitude on the share price. Read Full Thread Follow Reply
25/7/2016 18:47	timbo003: Presumably this new article on Proactiveinvestor was the catalyst for the excitement today: http://www.proactiveinvestors.co.uk/companies/news/128572/evgen-pharma-and-the-power-of-plants-for-potential-drug-breakthrough-128572.html It's well written but contains no new news, so it wouldn't surprise me if the share price drifts back down again. I suspect the next significant news will be MRHA approval for the Metastatic breast cancer study Read Full Thread Follow Reply
30/10/2011 19:43	call-logger: Subject to the Court sanctioning the Scheme and the satisfaction of certain other outstanding conditions, it is expected that the last day for dealings in Evolution Shares will be 6 December 2011 and the Scheme will become effective on 7 December 2011. If you're selling, the takeover date doesn't really matter to you. The share price is now purely based on the market's view of Investec Read Full Thread Follow Reply
08/11/2009 18:17	plast: well if that is the result to the share price, then they can sell some more. Read Full Thread Follow Reply
08/1/2008 19:48	msy: No share price movement to the following news? BES could make full bid for Evolution if strategic alliance goes well LISBON (Thomson Financial) - Banco Espirito Santo could make a full bid for the Evolution Group, in which it bought a 9.95 pct stake yesterday, if the strategic alliance between the Portuguese bank and the UK broker goes well, the Daily Telegraph reported, without citing a source. According to the newspaper, BES bought the stake in Evolution to offer international clients access to the London market through the UK-based financial holding's investment arm. If the arrangement works well, BES may make an offer for the whole of the UK business which is worth 260 mln stg, the paper said. Yesterday, BES investment unit BESI said it acquired its 9.95 pct stake for around 26.1 mln stg (about 35.5 mln eur). Evolution might be attractive to a buyer because the volatile earnings from its investment banking business were offset by more steady profits from its asset-management business, gained when it bought Williams de Broe from ING in 2006, the paper added. Read Full Thread Follow Reply

Evgen Pharma share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:42 V: D:20180424 21:10:55